Breed s Hill Capital LLC Makes New $479,000 Investment in Zoetis Inc. (NYSE:ZTS)

Breed s Hill Capital LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 2,427 shares of the company’s stock, valued at approximately $479,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Blue Bell Private Wealth Management LLC increased its position in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the period. Independence Bank of Kentucky increased its stake in Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the period. Ramirez Asset Management Inc. bought a new position in Zoetis during the 3rd quarter valued at $35,000. First Financial Corp IN raised its holdings in shares of Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after purchasing an additional 79 shares in the last quarter. Finally, EdgeRock Capital LLC acquired a new stake in Zoetis during the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares in the company, valued at $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Stock Up 1.9 %

ZTS stock traded up $3.21 during midday trading on Thursday, reaching $168.13. The company had a trading volume of 2,108,446 shares, compared to its average volume of 3,184,266. The company has a 50 day moving average of $166.94 and a two-hundred day moving average of $178.83. The company has a market capitalization of $76.72 billion, a P/E ratio of 32.40, a PEG ratio of 2.57 and a beta of 0.86. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, equities research analysts expect that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on ZTS. Barclays dropped their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. The Goldman Sachs Group decreased their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.